25 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
7 Mar 24
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
4:05pm
-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
14 Nov 23
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
4:10pm
) and (iii) mRNA drug substance along with drug product manufacturing expertise. The Company has an ongoing global collaboration for innovative mRNA
8-K
EX-99.1
ggii8f9jbh p5
13 Dec 22
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
4:14pm
8-K
EX-99.1
00prlbd
1 Nov 22
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
6:36pm
8-K
1msxfz31j gonx0y
1 Sep 22
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of
5:09pm
10-K
4ip0s
16 Mar 20
Annual report
11:09am
8-K
EX-99.1
5ben35n3
4 Mar 20
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR TechnologyTM
8:52am
8-K
EX-99.1
jmzq4dtjt
7 Nov 19
Regulation FD Disclosure
4:01pm
DEF 14A
1fk4z3k2vfqb9
1 Oct 19
Definitive proxy
6:07am